🟢 Connect Biopharma is trading 10.7% up in pre-market ahead of its August 12, 2026 earnings report

Connect Biopharma is trading 10.7% up at $2.38 ahead of its Q2 2026 earnings report, expected on August 12, 2026.

• Analysts expect a $0.32-per-share loss and zero revenue; attention remains focused on the company’s rademikibart development timeline.
• The move appears tied to positioning ahead of the report rather than a newly announced clinical or regulatory event.
• Broader markets are modestly higher, offering limited additional support; confidence is medium because no fresh company announcement was identified.